SB17170 Phase 2 Trial in IPF Patients

Sponsor
SPARK Biopharma
Study ID
NCT06747923
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • IPF
  • Idiopathic Pulmonary Fibrosis
  • Idiopathic Pulmonary Fibrosis (IPF)

Eligibility Criteria

Sex
ALL
Age
40 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SB17170 — DRUG
    Taking SB17170 orally once a day
  • Placebo — DRUG
    Taking Placebo orally once a day

Study Details

This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.

Key Dates

Start date
Jan 27, 2025
Status verified
Nov 2025
Primary completion
May 30, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SB17170 of A mg, Single dose
  • Experimental: SB17170 of B mg, Single dose
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change from baseline in FVC (ml) [ Time Frame: Week 12 ]

Central Contacts

Related Studies